Understanding the Market | XUANZHUBIO-B surged over 14%, rising more than 2.3 times from the offering price as the company enters a period of commercial explosion this year
XUANZHUBIO-B's stock price rose more than 14% in the afternoon, reaching a high of HKD 38.8, an increase of over 234% compared to the offering price of HKD 11.6. As of the time of writing, the stock price is HKD 38.12, with a trading volume of HKD 32.2915 million. The company was spun off from Sihuan Pharmaceutical and is actively developing a variety of drugs, expecting to enter a commercialization boom period in 2025, forming a product matrix centered on digestive and oncology drugs
According to Zhitong Finance APP, XUANZHUBIO-B (02575) rose over 14% in the afternoon, reaching a high of HKD 38.8, an increase of over 234% compared to the offering price of HKD 11.6. As of the time of publication, it was up 12.12%, trading at HKD 38.12, with a transaction volume of HKD 32.2915 million.
The prospectus shows that XUANZHUBIO was spun off from the Hong Kong-listed company Sihuan Pharmaceutical (00460), representing a typical "H-share spin-off." As of the last actual feasible date, XUANZHUBIO has more than ten drug assets actively under development, covering digestive system diseases, tumors, and non-alcoholic steatohepatitis (NASH), including three NDA-approved assets, one drug project in the NDA registration stage, one drug project in the Phase III clinical trial stage, four drug projects in the Phase I clinical trial stage, and five that have received IND approval.
Zhitong Finance APP pointed out in “Dual-Engine Drive + Three Carriages of Commercialization, XUANZHUBIO Aims to Set a New Benchmark for Innovative Drugs in Hong Kong” that with the support of the dual-engine drive of digestion and tumors, XUANZHUBIO is expected to enter a period of commercial explosion in 2025: the core tumor drugs Pyrotinib Tablets and Dirocitinib Tablets have been consecutively approved, along with the previously approved core product proton pump inhibitor Anaprazole Sodium, thus forming a product matrix of commercial "three carriages," representing the company's hardcore innovation and commercialization parallel development strategy gaining dual recognition from the industry and the market
